GlaxoSmithKline's (GSK -1.8% in London) MAGE-A3 lung-cancer immunotherapeutic failed to meet two out of three primary goals in a Phase III trial.
The therapy didn't significantly boost disease-free survival in non-small cell lung cancer patients vs a placebo in either the overall MAGE-A3 positive population or in MAGE-A3-positive patients who did not receive chemotherapy.
MAGE-A3 is a tumor-specific antigen found in cancer but not in normal cells.
GSK will continue the trial to assess the third primary endpoint, which is designed to identify a subset of MAGE-A3 positive patients that may benefit from the treatment. (PR)